- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-601, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,153
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors or Lymphomas
- Interventions
- CA-170
- Drug
- Lead sponsor
- Curis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more
- Conditions
- Heart Diseases, Left Ventricular Dysfunction
- Interventions
- Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
- Drug · Other
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Breast Cancer, Non-small Lung Cancer
- Interventions
- Docetaxel, GDC-0032, Paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more
- Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Ficlatuzumab, Cetuximab, Placebo
- Biological · Other
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 28
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
- Conditions
- CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Subcutaneous Blinatumomab
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Cancer
- Interventions
- BNT162b2 vaccine
- Biological
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Sepsis
- Interventions
- Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples
- Procedure · Drug · Device + 1 more
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Alcoholism
- Interventions
- Ketamine and Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 30 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2015
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Hyperpalatable Foods, Abuse Liability
- Interventions
- Full Dose HPF, Modified Dose- No Fat, Modified Dose- No Sodium, Jicama Root Vegetable Chip- Negative Control
- Other
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Lawrence, Kansas
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- palbociclib, Cetuximab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more
- Conditions
- Breast Cancer
- Interventions
- Entinostat, Atezolizumab, Placebo
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more
- Conditions
- HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
- Interventions
- Part 1, Part 2, Part 3
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Chicago, Illinois
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
- Procedure · Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Carboplatin, Sunitinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 14
- States / cities
- Fort Lauderdale, Florida • Fort Myers, Florida • Gainesville, Georgia + 9 more
- Conditions
- Advanced and Selected Solid Tumors
- Interventions
- BKM120, GSK1120212
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Hyperglycaemia (Diabetic)
- Interventions
- Dichloroacetate, Placebo oral capsule
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986449, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more
- Conditions
- HIV Infections, HIV Seronegativity
- Interventions
- APL 400-003
- Biological
- Lead sponsor
- Wyeth-Lederle Vaccines
- Industry
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
- Interventions
- BMN-673, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Pamela Munster
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Head and Neck Cancer, HPV
- Interventions
- Volrustomig, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Mirdametinib, Palbociclib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more